A clinical trial with 131 patients with HER2-negative breast cancer demonstrated that a FMD adhered to for 3 days prior to chemotherapy administration remained safe, effective, and lowered DNA damage in T cells as one metric of enhanced sensitivity to chemotherapeutic response [211]. This evidence concerns the gene ERBB2 and breast cancer.